Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Precemtabart Tocentecan · M-9140

Antibody-drug conjugate · Kills target cells, directed at carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) · developed by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 1 Most advanced trial (none active)
MRK Developer

What is Precemtabart Tocentecan?

Precemtabart tocentecan is an antibody-drug conjugate made of a human IgG1 monoclonal antibody against CEACAM5, linked to the topoisomerase I inhibitor exatecan. After the antibody binds CEACAM5 on tumor cells and is internalized, exatecan is released and disrupts DNA replication, causing cell cycle arrest and apoptosis. It is being studied in solid tumors and colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
M-9140
Drug type
Antibody-drug conjugate
Targets
carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
Mechanism
Kills target cells, directed at carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
Pathways
DNA topoisomerase I inhibition, DNA replication inhibition, cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (MRK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
V97BV45YBZ

Conditions studied

Colorectal CancerSolid Tumors

Other drugs acting on CEACAM5

More from Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Precemtabart Tocentecan

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.